{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=EGFR-mutated+NSCLC+%28Disorder%29", "query": { "condition": "EGFR-mutated NSCLC (Disorder)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 140, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=EGFR-mutated+NSCLC+%28Disorder%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T02:59:40.822Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06868485", "title": "A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "WSD0922-FU Tablets, Dose level A", "type": "DRUG" }, { "name": "WSD0922-FU Tablets, Dose level B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wayshine Biopharm, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2025-08-18", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-09-26T02:59:40.822Z", "location_count": 8, "location_summary": "Oxnard, California • Weston, Florida • Detroit, Michigan + 5 more", "locations": [ { "city": "Oxnard", "state": "California" }, { "city": "Weston", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Manahawkin", "state": "New Jersey" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06868485" }, { "nct_id": "NCT04765059", "title": "A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin", "type": "DRUG" }, { "name": "Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 98, "start_date": "2021-09-12", "completion_date": "2027-06-02", "has_results": true, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-09-26T02:59:40.822Z", "location_count": 2, "location_summary": "Silver Spring, Maryland • Boston, Massachusetts", "locations": [ { "city": "Silver Spring", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04765059" }, { "nct_id": "NCT07185997", "title": "Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small-Cell Lung Cancer", "Metastatic Non-Small-Cell Lung Cancer", "Advanced Non-Small-Cell Lung Cancer", "EGFR P-Loop and Alpha C-Helix Compressing", "EGFR PACC", "EGFR Uncommon Mutations" ], "interventions": [ { "name": "Firmonertinib", "type": "DRUG" }, { "name": "EGFR-TKI inhibitor based on investigator's choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ArriVent BioPharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 480, "start_date": "2025-12-17", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-26T02:59:40.822Z", "location_count": 20, "location_summary": "Fullerton, California • Los Angeles, California • Orange, California + 17 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07185997" }, { "nct_id": "NCT05498428", "title": "A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-small-Cell Lung" ], "interventions": [ { "name": "Amivantamab", "type": "DRUG" }, { "name": "Lazertinib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Direct Oral Anticoagulant (DOAC)", "type": "DRUG" }, { "name": "Low Molecular Weight Heparin (LMWH)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 520, "start_date": "2022-11-11", "completion_date": "2028-08-18", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-26T02:59:40.822Z", "location_count": 26, "location_summary": "La Jolla, California • Orange, California • Stanford, California + 21 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05498428" }, { "nct_id": "NCT02335944", "title": "Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Capmatinib", "type": "DRUG" }, { "name": "Nazartinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 177, "start_date": "2015-01-13", "completion_date": "2020-11-10", "has_results": true, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-09-26T02:59:40.822Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02335944" }, { "nct_id": "NCT04141644", "title": "Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2020-08-20", "completion_date": "2028-04-30", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-09-26T02:59:40.822Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04141644" }, { "nct_id": "NCT03515837", "title": "Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "saline solution", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 492, "start_date": "2018-06-29", "completion_date": "2023-10-02", "has_results": true, "last_update_posted_date": "2024-11-22", "last_synced_at": "2026-09-26T02:59:40.822Z", "location_count": 19, "location_summary": "Los Angeles, California • Monterey, California • Orange, California + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Monterey", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03515837" }, { "nct_id": "NCT05401110", "title": "Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Lung Cancer" ], "interventions": [ { "name": "Osimertinib", "type": "DRUG" }, { "name": "Carotuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karen Reckamp, MD, MS", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2023-09-15", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-26T02:59:40.822Z", "location_count": 5, "location_summary": "Beverly Hills, California • Los Angeles, California • Torrance, California", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05401110" }, { "nct_id": "NCT07070232", "title": "A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BNT326", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Paroxetine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1438, "start_date": "2025-08-12", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-26T02:59:40.822Z", "location_count": 19, "location_summary": "Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07070232" }, { "nct_id": "NCT00997334", "title": "Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David M. Jackman, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2010-02", "completion_date": "2017-01", "has_results": true, "last_update_posted_date": "2018-02-23", "last_synced_at": "2026-09-26T02:59:40.822Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00997334" } ] }